Rainer Kramer
Vermögen: - $ am 31.08.2026
Vermögen: - $ am 31.08.2026
Dr. Rainer Kramer is a Chief Business Officer at Immatics Biotechnologies GmbH and a Chief Business Officer at Immatics NV.
He is on the Board of Directors at iOmx Therapeutics AG and Immatics US, Inc. Dr. Kramer was previously employed as a Chief Business Officer by Signature Diagnostics AG, a Vice President-Business Development by Jerini AG, a Head-Business Development by MorphoSys AG, and a Principal by Amgen, Inc. He received his undergraduate degree from the University of Regensburg and a doctorate degree from Max Planck Institute of Neurobiology.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMATICS N.V. -.--% | 18.03.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMATICS N.V. | Corporate Officer/Principal | 01.01.2012 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Corporate Officer/Principal | 01.04.2012 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Direktor/Vorstandsmitglied | - |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology Develops immunotherapy treatments for cancer patients | Direktor/Vorstandsmitglied | 20.07.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
Signature Diagnostics AG
Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Operates as a molecular diagnostics company | Corporate Officer/Principal | 01.05.2012 |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Develops novel drugs | Corporate Officer/Principal | 01.08.2009 |
| MORPHOSYS AG | Corporate Officer/Principal | 01.01.2003 |
| AMGEN INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Develops novel drugs | Health Technology |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
University of Regensburg
University of Regensburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Signature Diagnostics AG
Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Operates as a molecular diagnostics company | Health Technology |
Max Planck Institute of Neurobiology
Max Planck Institute of Neurobiology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology Develops immunotherapy treatments for cancer patients | Health Technology |
Immatics NV
Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen